Randomized, double-blind, placebo-controlled single ascending dose study to assess the safety and tolerability of AP30663 in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 20 Feb 2018
At a glance
- Drugs AP-30663 (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Acesion Pharma
- 18 Feb 2018 Status changed from planning to recruiting.
- 13 Feb 2018 New trial record
- 08 Feb 2018 According to an Acesion Pharma media release, this trial will be onducted at the Centre for Human Drug Research (CHDR) in the Netherlands.